Design, synthesis, and structure–activity relationships of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as inhibitors of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immune checkpoint pathway-Reference-Cited by-同舟云学术

Design, synthesis, and structure–activity relationships of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as inhibitors of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immune checkpoint pathway

Published:2022-07-14 Issue:10 Volume:31 Page:1716-1739
ISSN:1054-2523
Container-title:Medicinal Chemistry Research
language:en
Short-container-title:Med Chem Res

Author:

Yang Jeffrey^ORCID,Basu Subhadwip^ORCID,Hu Longqin^ORCID

Funder

Rutgers University Foundation

Publisher

Springer Science and Business Media LLC

Subject

Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics

Link

https://link.springer.com/content/pdf/10.1007/s00044-022-02926-7.pdf

Reference34 articles.

1. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–42. https://doi.org/10.1111/j.1600-065X.2010.00923.x

2. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14:1212–8. https://doi.org/10.1038/ni.2762

3. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10. https://doi.org/10.1016/j.immuni.2013.07.012

4. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–30. https://doi.org/10.1038/nature21349

5. Liu X, Hogg GD, DeNardo DG. Rethinking immune checkpoint blockade: ‘beyond the T cell’. J Immunother Cancer. 2021;9:e001460. https://doi.org/10.1136/jitc-2020-001460

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nonsymmetrically Substituted 1,1′-Biphenyl-Based Small Molecule Inhibitors of the PD-1/PD-L1 Interaction;ACS Medicinal Chemistry Letters;2024-06-03

2. Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges;Frontiers in Immunology;2024-04-10